10314-99-5

Basic information

• Product Name: Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate
• Synonyms: Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate, 95+%;Piperidine-4-carbonyl chloride, N-CBZ protected;Benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate;Phenylmethyl 4-(chlorocarbonyl)-1-piperidinecarboxylate;Benzyl-4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate 95%;benzyl 4-(carbonochloridoyl)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-(chlorocarbonyl)-, phenylmethyl ester;BENZYL 3-(CHLOROCARBONYL)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 10314-99-5
• Molecular Formula: C₁₄H₁₆ClNO₃
• Molecular Weight: 281.73
• Product Categories: pharmacetical
• Mol File: 10314-99-5.mol

Chemical Properties

• Boiling Point: 396.6 °C at 760 mmHg
• Flash Point: 193.6 °C
• Appearance: /
• Density: 1.269 g/cm³
• Vapor Pressure: 1.69E-06mmHg at 25°C
• Refractive Index: 1.557
• PKA: -2.51±0.40(Predicted)
• CAS DataBase Reference: Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate(10314-99-5)
• EPA Substance Registry System: Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate(10314-99-5)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 3265
• Hazardous Substances Data: 10314-99-5(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate is used as a research chemical for [application reason] in the field of organic chemistry. Its presence of a pyridine ring and a benzyl group suggests that it may be involved in the synthesis of complex organic molecules or used as an intermediate in the preparation of pharmaceutical compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, Benzyl 4-(chlorocarbonyl)tetrahydro-1(2H)-pyridinecarboxylate is used as a key intermediate for [application reason] in the synthesis of potential drug candidates. The pyridine ring is a common structural element in many drugs, and the compound's properties may contribute to the development of new therapeutic agents.

InChI:InChI=1/C14H16ClNO3/c15-13(17)12-7-4-8-16(9-12)14(18)19-10-11-5-2-1-3-6-11/h1-3,5-6,12H,4,7-10H2

Upstream product

• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 498-94-2 isonipecotic acid 
• 501-53-1 benzyl chloroformate 
• 2971-79-1 isonipecotic acid methyl ester 
• 138163-07-2 piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-methyl ester 

Downstream Products

• 73415-79-9 4-(2-Hydroxy-ethylcarbamoyl)-piperidine-1-carboxylic acid benzyl ester 
• 171725-33-0 2-(N'-Cbz-piperidine-4-carbonyl)-N-Boc-aniline 
• 498-94-2 isonipecotic acid 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 216502-70-4 4-{5-[(S)-2-tert-Butoxycarbonyl-2-(2,2,2-trifluoro-acetylamino)-ethyl]-2-methoxy-phenylcarbamoyl}-piperidine-1-carboxylic acid benzyl ester 
• 220031-94-7 1-(1-benzyloxycarbonyl-4-piperidinylcarbonyl)-4-(t-butoxycarbonylamino)piperidine 
• 333988-72-0 1-(Benzyloxycarbonyl)-N-[3-(4-benzyl-1-piperidinyl)propyl]-N-phenyl-3-piperidine Carboxamide 
• 333988-65-1 1-(Benzyloxycarbonyl)-N-[3-(4-benzyl-1-piperidinyl)propyl]-N-phenyl-4-piperidinecarboxamide 
• 148148-48-5 4-(N-methoxy-N-methyl-carbamoyl)-piperidine-1-carboxylic acid benzyl ester 
• 333988-66-2 N-[3-(4-Benzyl-1-piperidinyl)propyl]-N-phenyl-4-piperidinecarboxamide 
• 752243-45-1 1-(4-chloro-3-nitro-benzenesulfonyl)-piperidine-4-carboxylic acid bis-(3-dimethylamino-propyl)-amide 

Relevant articles and documents

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 μM maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes.

Nickel-Catalyzed Decarboxylative Alkenylation of Anhydrides with Vinyl Triflates or Halides

Decarboxylative cross-coupling of aliphatic acid anhydrides with vinyl triflates or halides was accomplished via nickel catalysis. This methodology works well with a broad array of substrates and features abundant functional group tolerance. Notably, our approach addresses the issue of safe and environmental installation of methyl or ethyl group into molecular scaffolds. The method possesses high chemoselectivity toward alkyl groups when aliphatic/aromatic mixed anhydrides are involved. Furthermore, diverse ketones could be modified with our strategy.

NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE

Provided is a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2. The present invention relates to a compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION. The compound has a selective MMP-9 production suppressive action, and is useful as a drug for the prophylaxis and/or treatment of autoimmune diseases such as rheumatoid arthritis and the like, inflammatory bowel diseases (ulcerative colitis, Crohn's disease) or osteoarthritis.

POTENT NON-UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE

The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of s

General synthetic strategies towards N-alkyl sulfoximine building blocks for medicinal chemistry and the use of dimethylsulfoximine as a versatile precursor

The sulfoximine group has great potential as a substituent in drug discovery, as evidenced by two new clinical candidates, and can be viewed as an isosteric alternative to the commonly used sulfone. Our aim was to improve the accessibility of this group by synthesising a diverse range of S-alkyl and N-alkyl sulfoximine building blocks with procedures that are applicable on a practical scale (>10 g). In particular, synthesis of the less well exploited N-alkyl sulfoximines and the use of dimethylsulfoximine as a versatile, commercially available precursor is discussed.

Chemical probes of a trisubstituted pyrrole to identify its protein target(s) in Plasmodium sporozoites

Malaria is a disease that has a major impact in many developing nations, especially on the African continent. There is a need to develop new therapeutics and prophylactic treatments against it. A trisubstituted pyrrole was recently found to inhibit infect

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based cyclin-dependent kinase 4 inhibitors: synthesis, biological evaluation and structure-activity relationships

The design, synthesis, and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitors are described. In continuing our program aim to search for potent CDK4 inhibitors, the introduction of a thiazole group at the hydrazone part has led to marked enhancement of chemical stability. Furthermore, by focusing on the optimization at the C-4′ position of the thiazole ring and the C-6 position of the thieno[2,3-d]pyrimidine moiety, compound 35 has been identified with efficacy in a xenograft model of HCT116 cells. In this paper, the potency, selectivity profile, and structure-activity relationships of our synthetic compounds are discussed.

Synthesis and pharmacological evaluation of 1-Alkyl-N-[(1R)-1-(4- fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents

We synthesized and evaluated inhibitory activity against T-type Ca 2+ channels for a series of 1-alkyl-N- [(1R)-1-(4-fluorophenyl)-2- methylpropyl]piperidine-4-carboxamide derivatives. Structure-activity relationship studies have revealed that the isopropyl substituent at the benzylic position plays an important role in exerting potent inhibitory activity, and the absolute configuration of the benzylic position was found to be opposite that of mibefradil, which was first launched as a new class of T-type Ca2+ channel blocker. Oral administration of N- [(1R)-1-(4-fluorophenyl)-2-methylpropyl]-1-[2-(3-methoxyphenyl)ethyl] piperidine-4-carboxamide (17f) lowered blood pressure in spontaneously hypertensive rats without inducing reflex tachycardia, an adverse effect often caused by traditional L-type Ca2+ channel blockers.

ANTIVIRAL COMPOUNDS

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.